Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
Lymphoma
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Late effects of treatment of non-Hodgkin lymphoma (NHL) have been observed. Impaired fertility may occur after exposure to alkylating agents.[8] For as many as three decades after diagnosis, patients are at a significantly elevated risk of developing second primary cancers, especially the following:[9-12]
Lung cancer.
Brain cancer.
Kidney cancer.
Bladder cancer.
Melanoma.
Hodgkin lymphoma.
Acute nonlymphocytic leukemia.
Left ventricular dysfunction was a significant late effect in long-term survivors of high-grade NHL who received more than 200 mg/m² of doxorubicin.[8,13]
Myelodysplastic syndrome and acute myelogenous leukemia are late complications of myeloablative therapy with autologous bone marrow or peripheral blood stem cell support, as well as conventional chemotherapy-containing alkylating agents.[10,14-21] Most of these patients show clonal hematopoiesis even before the transplant, suggesting that the hematologic injury usually occurs during induction or reinduction chemotherapy.[16,22,23] A series of 605 patients who received autologous bone marrow transplant (BMT) with cyclophosphamide and total-body radiation therapy (as conditioning) were followed for a median of 10 years. The incidence of a second malignancy was 21%, and 10% of those malignancies were solid tumors.[24]
A study of young women who received autologous BMT reported successful pregnancies with children born free of congenital abnormalities.[25] Late-occurring venous thromboembolism can occur after allogeneic or autologous BMT.[26]
Some patients have osteopenia or osteoporosis at the start of therapy; bone density may worsen after therapy for lymphoma.[27]
Sources: 27
Long-term impaired immune health was evaluated in a retrospective cohort study of 21,690 survivors of diffuse large B-cell lymphoma from the California Cancer Registry. Elevated incidence rate ratios were found up to 10 years later for pneumonia (10.8-fold), meningitis (5.3-fold), immunoglobulin deficiency (17.6-fold), and autoimmune cytopenias (12-fold).[28] Similarly, there are impaired humoral responses to COVID-19 virus vaccination in patients with lymphoma who receive B-cell–directed therapies.[29,30]
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of follicular large cell lymphoma is more similar to the treatment of aggressive NHL than it is to the treatment of indolent NHL. In support of this approach, treatment with high-dose chemotherapy and autologous hematopoietic peripheral SCT shows the same curative potential in patients with follicular large cell lymphoma who relapse as it does in patients with diffuse large cell lymphoma who relapse.[47][Level of evidence C1]
Sources: 47 · Level of evidence C1
Among patients who had received two prior lines of therapy, more than one-half who received CAR T-cell therapy with lisocabtagene maraleucel had a disease response.[38][Level of evidence C3]
Sources: 38 · Level of evidence C3
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of Burkitt lymphoma/diffuse small noncleaved-cell lymphoma involves aggressive multidrug regimens in combination with rituximab, similar to those used for the advanced-stage aggressive lymphomas (DLBCL).[54-57] Aggressive combination chemotherapy, which is modeled after that used in childhood Burkitt lymphoma, has been successful for adult patients with more than 60% of advanced-stage patients free of disease at 5 years.[58-61] Adverse prognostic factors include bulky abdominal disease and a high serum LDH level. Patients with Burkitt lymphoma have a 20% to 30% lifetime risk of CNS involvement. Prophylaxis with intrathecal chemotherapy is required as part of induction therapy.[62] Patients with HIV-associated Burkitt lymphoma also benefit from less-toxic modification of the aggressive multidrug regimens in combination with rituximab.[63][Level of evidence C3] For more information, see Primary Central Nervous System Lymphoma Treatment and AIDS-Related Lymphoma Treatment.
Sources: 54 · 57 · 58 · 61 · 62 · 63 · Level of evidence C3 · Primary Central Nervous System Lymphoma Treatment · AIDS-Related Lymphoma Treatment
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Therapy is usually modeled after the treatment of comparably staged diffuse large cell lymphomas.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
In some cases, withdrawal of immunosuppression results in eradication of the lymphoma.[76,77] When this is unsuccessful or not feasible, a course of rituximab may be considered because it has shown durable remissions in approximately 60% of patients and a favorable toxicity profile.[76,78,79] If these measures fail, doxorubicin-based combination chemotherapy (R-CHOP) is recommended, although some patients can avoid cytotoxic therapy.[79,80] Localized presentations can be controlled with surgery or radiation therapy alone. These localized mass lesions, which may grow over a period of months, are often phenotypically polyclonal and tend to occur within weeks or a few months after transplant.[73] Multifocal, rapidly progressive disease occurs late after transplant (>1 year) and is usually phenotypically monoclonal and associated with EBV.[81] These patients may have durable remissions using standard chemotherapy regimens for aggressive lymphoma.[81-83] Instances of EBV-negative PTLD occur even later (median, 5 years posttransplant) and have a worse prognosis; R-CHOP can be given directly in this circumstance.[84] A sustained clinical response in patients with chemotherapy-refractory disease was attained using an immunotoxin (anti-CD22 B-cell surface antigen antibody linked with ricin, a plant toxin).[85] An anti-interleukin-6 monoclonal antibody is also under clinical evaluation.[86]
Sources: 76 · 77 · 76 · 78 · 79 · 79 · 80 · 73 · 81 · 81 · 83 · 84 · 85 · 86
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Therapy is modeled after the treatment of comparably staged diffuse large cell lymphomas, but the optimal approach remains to be defined.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of aggressive non-Hodgkin lymphoma (NHL) depends on the histological type and stage. Many of the improvements in survival have been made because of clinical trials that have attempted to improve conventional or standard therapy.
In asymptomatic patients with indolent forms of advanced NHL, treatment may be deferred until the patient becomes symptomatic as the disease progresses. When treatment is deferred, the clinical course of patients with indolent NHL varies; frequent and careful observation is required so that effective treatment can be initiated when the clinical course of the disease accelerates. Some patients have a prolonged indolent course, but others have disease that rapidly evolves into more aggressive types of NHL that require immediate treatment.
Radiation techniques differ somewhat from those used in the treatment of Hodgkin lymphoma. The dose of radiation therapy usually varies from 25 Gy to 50 Gy and is dependent on factors that include the histological type of lymphoma, the patient’s stage and overall condition, the goal of treatment (curative or palliative), the proximity of sensitive surrounding organs, and whether the patient is being treated with radiation therapy alone or in combination with chemotherapy. Given the patterns of disease presentations and relapse, treatment may need to include unusual sites such as Waldeyer ring, epitrochlear nodes, or mesenteric nodes. The associated morbidity of the treatment must be considered carefully. Most patients who receive radiation are treated on only one side of the diaphragm. Localized presentations of extranodal NHL may be treated with involved-field techniques with significant (>50%) success.
In situations where mediastinal radiation therapy would encompass the left side of the heart or would increase breast cancer risk in young female patients, proton therapy may be considered to reduce radiation dose to organs at risk.[1] For more information, see the Superior Vena Cava Syndrome section in Cardiopulmonary Syndromes.
Sources: 1 · Superior Vena Cava Syndrome
| Stage | Treatment Options |
|---|---|
| BMT = bone marrow transplant; CAR = chimeric antigen receptor; CNS = central nervous system; IF-XRT = involved-field radiation therapy; Pola-R-CHP = polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-ACVBP = rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; SCT = stem cell transplant. | |
| Aggressive Stage I and Aggressive, Contiguous Stage II B-cell NHL | R-CHOP with or without IF-XRT |
| R-ACVBP | |
| Aggressive, Noncontiguous Stage II/III/IV B-cell NHL | Pola-R-CHP (for IPI 2 to 5) |
| R-CHOP | |
| Radiation therapy consolidation to sites of bulky disease (under clinical evaluation) | |
| Aggressive, Recurrent B-cell NHL | CAR T-cell therapy for primary refractory disease or relapse within 1 year (or for relapse after autologous SCT) |
| BMT or SCT consolidation | |
| Tafasitamab plus lenalidomide | |
| Bispecific T-cell engagers | |
| Polatuzumab vedotin plus rituximab and bendamustine | |
| Loncastuximab tesirine | |
| Rituximab plus lenalidomide | |
| Palliative radiation therapy | |
| B-cell Lymphoblastic Lymphoma/Acute Lymphoblastic Leukemia | See Acute Lymphoblastic Leukemia Treatment |
| Diffuse Small Noncleaved-Cell/Burkitt Lymphoma | Aggressive multidrug regimens |
| CNS prophylaxis | |
Sources: R-CHOP with or without IF-XRT · Pola-R-CHP · R-CHOP · Radiation therapy consolidation to sites of bulky disease · CAR T-cell therapy for primary refractory disease or relapse within 1 year · BMT or SCT consolidation · Tafasitamab plus lenalidomide · Bispecific T-cell engagers · Polatuzumab vedotin plus rituximab and bendamustine · Loncastuximab tesirine · Rituximab plus lenalidomide · Palliative radiation therapy · Acute Lymphoblastic Leukemia Treatment · Aggressive multidrug regimens · CNS prophylaxis
Even though existing treatments cure a significant fraction of patients with lymphoma, numerous clinical trials that explore treatment improvements are in progress. If possible, patients can participate in these studies. Standardized guidelines for response assessment have been suggested for use in clinical trials.[2]
Sources: 2
Several retrospective reviews suggest that routine surveillance scans offer little to no value in patients with diffuse-large B-cell lymphoma (DLBCL) who have attained a clinical complete remission after induction therapy. Prognostic value is also difficult to identify for an interim positron emission tomography-computed tomography scan during induction therapy for DLBCL.[3-6]
Aggressive lymphomas are increasingly seen in patients with HIV. Treatment of these patients requires special consideration. For more information, see AIDS-Related Lymphoma Treatment
Sources: AIDS-Related Lymphoma Treatment
In addition to screening for HIV among patients with aggressive lymphomas, active hepatitis B or hepatitis C can be assessed before treatment with rituximab and/or chemotherapy.[7,8] Patients with detectable hepatitis B virus (HBV) benefit from prophylaxis with entecavir in the context of rituximab therapy.[9,10] Patients with a resolved HBV infection (defined as hepatitis B surface antigen-negative but hepatitis B core antibody-positive) are at risk of reactivation of HBV and require monitoring of HBV DNA. In a retrospective study of 326 patients, prophylactic nucleoside analogue therapy lowered HBV reactivation from 10.8% to 2.1%.[11] Similarly, prophylaxis for herpes zoster with acyclovir or valacyclovir and prophylaxis for Pneumocystis with trimethoprim/sulfamethoxazole or dapsone are usually given to patients receiving rituximab with or without combination chemotherapy. Long-term impaired immune health was evaluated in a retrospective cohort study of 21,690 survivors of DLBCL from the California Cancer Registry. Elevated incidence rate ratios were found up to 10 years later for pneumonia (10.8-fold), meningitis (5.3-fold), immunoglobulin deficiency (17.6-fold), and autoimmune cytopenias (12-fold).[12]
Among 2,508 patients in a Danish registry, the incidence of doxorubicin-induced congestive heart failure increased for 115 NHL survivors with a history of cardiac disease (hazard ratio [HR], 2.71; 95% confidence interval [CI], 1.15−6.36) and/or multiple cardiovascular risk factors (HR, 2.86; 95% CI, 1.56−5.23).[13]
Sources: 13
For more information, see Primary Central Nervous System Lymphoma Treatment.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Patients with aggressive stage I or aggressive, contiguous stage II diffuse large B-cell lymphoma (DLBCL) are candidates for combination chemotherapy with or without involved-field radiation therapy (IF-XRT).
Patients with a resolved hepatitis B virus (HBV) infection (defined as hepatitis B surface antigen-negative but hepatitis B core antibody-positive) are at risk of reactivation of HBV and require monitoring of HBV DNA. In a retrospective study of 326 patients, prophylactic nucleoside analogue therapy lowered HBV reactivation from 10.8% to 2.1%.[1]
Sources: 1
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Four case series involving more than 100 patients with stage IE or IIE disease (with or without mucosa-associated lymphatic tissue) and with positive Helicobacter pylori infection. The series reported that more than 50% of patients attained a durable complete remission after appropriate antibiotic therapy to eradicate H. pylori.[2-5][Level of evidence C3]
Sources: 2 · 5 · Level of evidence C3
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment options for aggressive stage I and aggressive, contiguous stage II B-cell non-Hodgkin lymphoma include:
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without IF-XRT.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Rituximab has efficacy in advanced-stage disease. However, its use is only supported by retrospective comparisons in studies of R-CHOP with or without radiation therapy.[8][Level of evidence C2]
Sources: 8 · Level of evidence C2
R-CHOP (four to six cycles).
R-CHOP (three to six cycles) + IF-XRT.
Evidence (R-CHOP with or without IF-XRT):
In a randomized prospective trial of 334 patients with nonbulky (≤7 cm) stage I or stage II DLBCL, after receiving four to six cycles of R-CHOP-14 (R-CHOP delivered every 2 weeks), patients were randomly assigned to undergo 40 Gy of radiation therapy or no radiation therapy.[9]
Sources: 9
In a randomized prospective trial of 334 patients with nonbulky (≤7 cm) stage I or stage II DLBCL, after receiving four to six cycles of R-CHOP-14 (R-CHOP delivered every 2 weeks), patients were randomly assigned to undergo 40 Gy of radiation therapy or no radiation therapy.[9]
After a median follow-up of 64 months, the 5-year event-free survival rate (89%–92%; P = .18) and 5-year overall survival (OS) rate (92%–96%; P = .32) were the same.[9][Level of evidence A1]Similar to the results of randomized studies of radiation therapy in the era before rituximab, radiation therapy can be deferred in patients with nonbulky early-stage disease. For patients unable to tolerate prolonged-course chemotherapy, three cycles of R-CHOP plus radiation therapy has produced equivalent results based on single-arm retrospective trials.[8]
Sources: 9 · Level of evidence A1 · 8
In a randomized prospective trial (NCT00278421) of 592 patients younger than 60 years with nonbulky (<7.5 cm) stage I or stage II DLBCL, patients were randomly assigned to receive either four or six cycles of R-CHOP (with an extra two cycles of rituximab after four cycles).[10]
Sources: NCT00278421 · 10
In a randomized prospective trial (NCT00278421) of 592 patients younger than 60 years with nonbulky (<7.5 cm) stage I or stage II DLBCL, patients were randomly assigned to receive either four or six cycles of R-CHOP (with an extra two cycles of rituximab after four cycles).[10]
With a median follow-up of 66 months, the 3-year progression-free survival (PFS) rate was 96% (95% confidence interval [CI], 94%−99%) for patients who received four cycles of R-CHOP, which was 3% better (lower limit of one-sided 95% CI was zero) than the PFS rate for patients who received six cycles, establishing noninferiority for the four-cycle regimen.[10][Level of evidence B1]
Sources: 10 · Level of evidence B1
A retrospective analysis at Memorial Sloan Kettering Cancer Center between 2001 and 2015 included 341 patients with stage I disease. The analysis found that 66% of patients had an extranodal presentation. After R-CHOP (or a similar regimen), with or without radiation therapy, the 5-year disease-free survival rate was 77%, and the 5-year OS rate was 94%.[11][Level of evidence C3] A multivariate analysis suggested that radiation therapy may improve outcomes for patients with extranodal disease that is positron emission tomography (PET)–positive at the end of therapy. This hypothesis needs confirmation in a prospective randomized trial.[11]
Sources: 11 · Level of evidence C3 · 11
In summary, for patients with favorable prognosis, nonbulky (<7 cm), stage I or stage II DLBCL, four cycles of R-CHOP are sufficient. For patients with an unfavorable prognosis, six cycles of R-CHOP or three cycles of R-CHOP and 40 Gy of radiation therapy can be used. Early-stage patients with bulky disease (>7.5 cm) have not been studied in randomized trials; combined-modality therapy with R-CHOP for four to six cycles plus radiation therapy is usually chosen. Although a retrospective study suggested that patients with stage I extranodal disease and a positive PET scan at the end of therapy may benefit from radiation therapy, this hypothesis must be confirmed in a prospective randomized trial.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The treatment of choice for patients with advanced stages of aggressive non-Hodgkin lymphoma (NHL) is combination chemotherapy, either alone or supplemented by local-field radiation therapy.[1]
Sources: 1
The following drug combinations are referred to in this section:
Pola-R-CHP: polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone.
R-CHOP: rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.
R-ACVBP: rituximab, an anti–CD20 monoclonal antibody + doxorubicin + cyclophosphamide + vindesine + bleomycin + prednisone.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment options for aggressive, noncontiguous stage II/III/IV B-cell NHL include:
Pola-R-CHP (for National Comprehensive Cancer Network International Prognostic Index [IPI] score of 2 to 5).
Sources: Pola-R-CHP
R-CHOP.
Sources: R-CHOP
Radiation therapy consolidation to sites of bulky disease (under clinical evaluation).
Sources: Radiation therapy consolidation to sites of bulky disease
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
R-CHOP has been compared with Pola-R-CHP. Polatuzumab is an antibody-drug conjugate composed of an anti-CD79B monoclonal antibody attached to vedotin (monomethyl auristatin E), a microtubule inhibitor.
Evidence (Pola-R-CHP):
A prospective, randomized study (POLARIX [NCT03274492]) of 879 patients with previously untreated diffuse large B-cell lymphoma (DLBCL) and an IPI score of 2 or higher compared R-CHOP with Pola-R-CHP.[2] Polatuzumab vedotin was substituted for vincristine to mitigate neurological toxicity.
A prospective, randomized study (POLARIX [NCT03274492]) of 879 patients with previously untreated diffuse large B-cell lymphoma (DLBCL) and an IPI score of 2 or higher compared R-CHOP with Pola-R-CHP.[2] Polatuzumab vedotin was substituted for vincristine to mitigate neurological toxicity.
At a median follow-up of 28.2 months, the 2-year progression-free survival (PFS) rate was significantly higher in the Pola-R-CHP group than in the R-CHOP group: 76.7% (95% confidence interval [CI], 72.7%–80.0%) versus 70.2% (95% CI, 65.8%–74.6%) (hazard ratio [HR], 0.73; 95% CI, 0.57–0.95; P = .02).[2][Level of evidence B1]
Sources: 2 · Level of evidence B1
The 2-year overall survival (OS) rate was 88.7% (95% CI, 85.7%–91.6%) for patients who received Pola-R-CHP and 88.6% (95% CI, 85.6%–91.6%) for patients who received R-CHOP (HR, 0.94; 95% CI, 0.65–1.37; P = .75).
A similar 7.7% improvement in 2-year PFS for Pola-R-CHP versus R-CHOP has been seen in an Asian subpopulation analysis from this trial.[3][Level of evidence C2]
Sources: 3 · Level of evidence C2
The follow-up interval was too short to establish whether the 6% improvement in the PFS rate will plateau or improve after 2 years, and there is no evidence of OS advantage. Nonetheless, updated outcomes with a median follow-up over 3 years showed continued improvement of PFS, prompting the U.S. Food and Drug Administration (FDA) to approve Pola-R-CHP. Pola-R-CHP is the first regimen in over 20 years to be approved by the FDA as a therapy for patients with noncontiguous stage II, stage III, and stage IV disease. The new regimen is more than twice the cost of R-CHOP using acquisition prices in 2022, and polatuzumab may not be available worldwide.
The Pola-R-CHP regimen demonstrated substantial efficacy for patients with DLBCL non–germinal center B-cell (GCB)-origin tumors, predominantly those with the ABC (activated B-cell) subtype.[4] In the POLARIX trial, the HRPFS for Pola-R-CHP versus R-CHOP in patients with ABC-subtype tumors was 0.34 (95% CI, 0.13–0.85), and the HROS for those patients was 0.27 (95% CI, 0.06–1.26). In contrast, no such benefit was observed for patients with GCB-subtype tumors in this trial. For Pola-R-CHP, the HRPFS was 1.18 (95% CI, 0.75–1.84), and the HROS was 1.64 (95% CI, 0.87–3.07). This differential efficacy in favor of the non-GCB or ABC subtype was seen in five prospective phase I and II trials of the Pola-R-CHP regimen in patients with relapsed or refractory disease, with a combined analysis of data showing a level of significance P < .001.[4] Combining the data for a randomized phase II trial studying Pola-R-CHP in patients with relapsed or refractory disease with data from the POLARIX trial in patients with previously untreated disease, the HRdisease relapse/progression/death was 0.25 for patients with ABC-subtype tumors and 0.98 for patients with GCB-subtype tumors (P < .001).[4] The only exception to this observation is the clear benefit of Pola-R-CHP in GCB patients with double-hit variants (MYC gene and BCL2 gene). Given the increased rates of febrile neutropenia in patients who receive Pola-R-CHP and the significant financial toxicity, it is reasonable to consider R-CHOP as a standard regimen for patients with GCB-subtype DLBCL without a double-hit variant. However, assessing the GCB subtype using commercially available immunophenotyping is less accurate than using the molecular genetic signatures used in the POLARIX study. Some patients may miss the PFS benefit of polatuzumab. Some clinicians err on the side of using Pola-R-CHP for GCB subtype when patients have other high-risk features (e.g., CD5 positivity or involvement in two or more extranodal sites).
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The following studies established R-CHOP as a standard regimen for patients with newly diagnosed DLBCL and noncontiguous stage II, stage III, and stage IV disease for over 20 years.[5] Dose intensification of R-CHOP by a 14-day versus a 21-day cycle did not result in improved outcomes.[6] R-CHOP is the preferred regimen when polatuzumab is not available or affordable, or when contraindicated due to adverse side effects.
Evidence (R-CHOP):
R-CHOP showed improved event-free survival (EFS) and OS compared with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) alone in 399 patients older than 60 years with advanced-stage DLBCL (EFS rate, 57% vs. 38%; P = .002, and OS rate, 70% vs. 57%; P = .007 at 2 years).[7][Level of evidence A1] At a median follow-up of 10 years, the OS rate of patients who received R-CHOP was 44% compared with 28% for patients who received CHOP (P < .0001).[8]
Sources: 7 · Level of evidence A1 · 8
Similarly, for 326 evaluable patients younger than 61 years, R-CHOP showed improved EFS and OS compared with CHOP alone (EFS rate, 79% vs. 59%, P = .001, and OS rate, 93% vs. 84%, P = .001 at 3 years).[9][Level of evidence A1]
Sources: 9 · Level of evidence A1
A randomized study (DSHNHL-1999-1A [NCT00052936]) of 1,222 patients older than 60 years compared R-CHOP given every 2 weeks for six or eight cycles with CHOP given every 2 weeks for six or eight cycles.[10] With a median follow-up of 72 months, the EFS favored R-CHOP given every 2 weeks for six or eight cycles (6-year EFS rate, 74% vs. 56%; P < .0001). The OS favored R-CHOP for only six cycles because of increased toxicity in the eight-cycle arm (6-year OS rate, 90% vs. 80%; P = .0004).[10][Level of evidence A1] There was no comparison with standard R-CHOP or CHOP given every 3 weeks.
Sources: DSHNHL-1999-1A · 10 · 10 · Level of evidence A1
A trial (NCT00140595) of 380 patients younger than 60 years with DLBCL and an age-adjusted IPI score of 1 randomly assigned patients to receive ACVBP and R-ACVBP plus consolidation with methotrexate, ifosfamide, etoposide, and cytarabine versus CHOP and rituximab.[11] With a median follow-up of 44 months, 3-year OS rates favored R-ACVBP (92% vs. 84%; HR, 0.44; 95% CI, 0.28–0.81, P = .007).[11][Level of evidence A1] The significantly worse toxicities with R-ACVBP, the narrow target population (<60 years with either elevated lactate dehydrogenase [LDH] or stage III-stage IV disease, but not both), and the lack of a confirmatory trial may inhibit adoption of R-ACVBP as a new standard of care.[12]
Sources: (NCT00140595) · 11 · 11 · Level of evidence A1 · 12
There is no validated trial for interim positron emission tomography–based treatment intensification.[13] R-CHOP has curative potential, even in patients older than 80 years who are frail and require reduced dosage of R-CHOP components. In a retrospective review of 239 patients, the 5-year cause-specific survival rate was 48% (95% CI, 41%−55%).[14][Level of evidence C3]
Sources: 13 · 14 · Level of evidence C3
Less than 10% of patients with DLBCL present with a concurrent indolent lymphoma at diagnosis, and these are predominantly of GCB phenotype. A retrospective review of 1,324 patients showed similar EFS (HR, 1.19) and OS (HR, 1.09).[15][Level of evidence C3] For 847 patients who were treated with R-CHOP and free of disease 24 months after therapy, the rate of indolent lymphoma relapse by 5 years was higher with a concurrent diagnosis of follicular lymphoma (7.4% vs. 2.1%, P < .01) and with a GCB phenotype (3.9% vs. 0.0% at 5 years, P = .02).[16]
Sources: 15 · Level of evidence C3 · 16
Modifications to R-CHOP to achieve improved efficacy continue to be explored in clinical trials.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
After R-CHOP induction chemotherapy (or similar regimens), the addition of involved-field radiation therapy to sites of initial bulky disease (≥5–10 cm) or to extralymphatic sites remains controversial.[17-19] Increased risks, such as long-term toxicities (e.g., second malignancies), must be considered.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Several randomized prospective trials evaluated the role of autologous BMT or SCT consolidation versus chemotherapy alone in patients with diffuse large cell lymphoma in first remission.[20-27]; [28-30][Level of evidence A1] Although some of these trials demonstrated significant increases in EFS (by 10% to 20%) among patients who received high-dose therapy, significant differences in OS could not be demonstrated prospectively in any of the series.
Sources: 20 · 27 · 28 · 30 · Level of evidence A1
Retrospective analyses of high-intermediate (two risk factors) or high-risk (more than three risk factors) patients as defined by IPI suggest improved survival with BMT in two of the trials.[21,27] These studies do not establish that high-dose consolidation is of value to patients with aggressive lymphoma who are truly at high risk of relapse, and they also demonstrate that EFS may be a poor surrogate for OS for these patients.[31]
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The National Comprehensive Cancer Network International Prognostic Index (IPI) for aggressive NHL (diffuse large cell lymphoma) identifies the following five significant risk factors prognostic of overall survival (OS) and their associated risk scores:[32]
Sources: 32
Age.
Age.
<40 years: 0.
41–60 years: 1.
61–75 years: 2.
>75 years: 3.
Stage III/IV: 1.
Performance status (PS) 2/3/4: 1.
Serum lactate dehydrogenase (LDH).
Serum lactate dehydrogenase (LDH).
Normalized: 0.
>1x–3x: 1.
>3x: 2.
Number of extranodal sites ≥2: 1.
Risk scores:
Low (0 or 1): 5-year OS rate, 96%; progression-free survival (PFS) rate, 91%.
Low intermediate (2 or 3): 5-year OS rate, 82%; PFS rate, 74%.
High intermediate (4 or 5): 5-year OS rate, 64%; PFS rate, 51%.
High (>6): 5-year OS rate, 33%; PFS rate, 30%.
Age-adjusted and stage-adjusted modifications of this IPI are used for younger patients with localized disease.[33] Shorter intervals of time between diagnosis and treatment appear to be a surrogate for poor prognostic biological factors.[34]
The BCL2 gene and rearrangement of the MYC gene or dual overexpression of the MYC gene, or both, confer a particularly poor prognosis.[35-38] Patients at high risk of relapse may be considered for clinical trials.[39] Molecular profiles of gene expression using DNA microarrays may help to stratify patients in the future for therapies directed at specific targets and to better predict survival after standard chemotherapy.[40]
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Patients with bulky and extensive lymphadenopathy and elevations of serum uric acid and LDH are at increased risk of tumor lysis syndrome, resulting in metabolic derangements such as hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and subsequent acute renal failure.[41] Treatment options include alkaline hydration, allopurinol, and rasburicase (a recombinant urate oxidase).[42]
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The CNS-IPI tool predicts which patients have a CNS relapse risk exceeding 10%.[43,44] It was developed by the German Lymphoma Study Group and validated by the British Columbia Cancer Agency database. The presence of four to six of the CNS-IPI risk factors (age >60 years, performance status ≥2, elevated LDH, stage III or IV disease, >1 extranodal site, or involvement of the kidneys or adrenal glands) was used to define a high-risk group for CNS recurrence (a 12% risk of CNS involvement by 2 years).[44]
CNS prophylaxis (usually with four to six doses of intrathecal methotrexate) is often recommended for patients with testicular involvement.[45-47][Level of evidence C3] A retrospective analysis of the German RICOVER studies compared intrathecal methotrexate with no prophylaxis in patients with DLBCL. This study was completed during the R-CHOP treatment era. With the possible exception of patients with testicular involvement, the analysis showed that intrathecal methotrexate did not reduce the risk of CNS disease.[48][Level of evidence C3]
Sources: 45 · 47 · Level of evidence C3 · 48 · Level of evidence C3
Some clinicians use high-dose intravenous (IV) methotrexate (usually four doses) as an alternative to intrathecal therapy because drug delivery is improved and patient morbidity is decreased.[43,49] Five retrospective studies and one network meta-analysis evaluating high-dose methotrexate alone in patients with high-risk DLBCL also showed no improvement in CNS relapse rate.[50-55][Level of evidence C3] Patients deemed at high risk for CNS relapse (e.g., patients with testicular, renal, or adrenal disease and three or more extranodal sites) may receive intrathecal methotrexate or high-dose IV methotrexate, but the lack of confirmatory randomized studies calls this standard into question and shows an urgent need for better therapeutics verified in clinical trials.[43,43] While there is insufficient evidence to support a significant benefit for CNS prophylaxis in most high-risk patients, the perceived risk of not treating for CNS relapse has often outweighed the lack of evidence for its efficacy.[43] Although patients with testicular involvement or kidney/adrenal involvement are considered an exception, there is only anecdotal benefit from intrathecal or high-dose IV methotrexate in reducing CNS recurrence.[45-47][Level of evidence C3]
Sources: 43 · 49 · 50 · 55 · Level of evidence C3 · 43 · 43 · 43 · 45 · 47 · Level of evidence C3
In retrospective analyses, the addition of rituximab to CHOP-based regimens has significantly reduced the risk of CNS relapse.[48,56][Level of evidence C3] Patients with CNS dissemination at diagnosis or at relapse usually receive rituximab and high doses of methotrexate and/or cytarabine followed by autologous SCT, but this approach has not been assessed in randomized trials.[57,58][Level of evidence C3]
Sources: 48 · 56 · Level of evidence C3 · 57 · 58 · Level of evidence C3
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
In a retrospective review of multiple international trials, 636 patients were identified as having refractory diffuse large B-cell lymphoma (DLBCL), which was defined as progression or stable disease during or just at completion of full-course chemotherapy or relapse within 1 year after autologous stem cell transplant (SCT).[1] With subsequent therapy, the objective response rate was 26%, complete response rate was 7%, median overall survival (OS) was 6.3 months, and only 20% of patients were alive at 2 years. Even with reinduction chemotherapy with planned autologous SCT, outcomes remain poor.[2]
Treatment options for aggressive, recurrent B-cell non-Hodgkin lymphoma include the following:
Chimeric antigen receptor (CAR) T-cell therapy for primary refractory disease or relapse within 1 year (or for relapse after autologous SCT).
Chimeric antigen receptor (CAR) T-cell therapy for primary refractory disease or relapse within 1 year (or for relapse after autologous SCT).
Axicabtagene ciloleucel (axi-cel).
Lisocabtagene maraleucel (liso-cel).
Bone marrow transplant (BMT)/SCT consolidation.
Tafasitamab plus lenalidomide.
Sources: Tafasitamab plus lenalidomide
Bispecific T-cell engagers.
Sources: Bispecific T-cell engagers
Glofitamab.
Sources: Glofitamab
Polatuzumab vedotin plus rituximab and bendamustine.
Sources: Polatuzumab vedotin plus rituximab and bendamustine
Loncastuximab tesirine.
Sources: Loncastuximab tesirine
Rituximab plus lenalidomide.
Sources: Rituximab plus lenalidomide
Palliative radiation therapy.
Sources: Palliative radiation therapy
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Patients with DLBCL who relapse during or within 2 months of receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy have primary refractory disease. Any patient with disease relapse within 1 year of R-CHOP chemotherapy or with primary refractory disease has a poor prognosis, even with reinduction using chemoimmunotherapy followed by autologous SCT.[1,2] Patients who received CAR T-cell therapy had a 40% to 50% 3-year progression-free survival (PFS) rate with a 40-month follow-up, a result equivalent retrospectively to autologous SCT in bone marrow registries.[3-6]
Three randomized trials compared chemoimmunotherapy followed by autologous SCT with CAR T-cell therapy with or without bridging chemoimmunotherapy for patients with high-risk relapsed disease, defined as primary refractory disease or relapse within 12 months of initial R-CHOP therapy.
Evidence (CAR T-cell therapy):
A prospective randomized trial included 359 patients with primary refractory disease or relapse within 12 months of initial R-CHOP chemotherapy. Patients received the CAR T-cell therapy axicabtagene ciloleucel (axi-cel) with only bridging steroids or second-line chemoimmunotherapy (usually R-ICE [rituximab, ifosfamide, etoposide, and carboplatin] or R-DHAP [rituximab, dexamethasone, high-dose cytarabine, and cisplatin]) followed by autologous SCT.[7,8]
A prospective randomized trial included 359 patients with primary refractory disease or relapse within 12 months of initial R-CHOP chemotherapy. Patients received the CAR T-cell therapy axicabtagene ciloleucel (axi-cel) with only bridging steroids or second-line chemoimmunotherapy (usually R-ICE [rituximab, ifosfamide, etoposide, and carboplatin] or R-DHAP [rituximab, dexamethasone, high-dose cytarabine, and cisplatin]) followed by autologous SCT.[7,8]
With a median follow-up of 47.2 months, the median OS was not reached in the axi-cel cohort and was 31.1 months in the chemoimmunotherapy cohort. The estimated 4-year OS rate was 54.6% for patients who received axi-cel and 46.0% for patients who received chemoimmunotherapy (hazard ratio [HR]death, 0.73; 95% confidence interval [CI], 0.54–0.98; P = .03).[8][Level of evidence A1]
Sources: 8 · Level of evidence A1
The median investigator-assessed PFS was 14.7 months in the axi-cel cohort and 3.7 months in the chemotherapy cohort (HR, 0.51; 95% CI, 0.38–0.67).
In the chemoimmunotherapy arm, 64% patients never received autologous SCT during the study because of inadequate response, progression, or death.[7]
Sources: 7
Clinically meaningful and statistically significant differences in quality of life were obtained in the CAR T-cell arm at day 100 and day 150, compared with the standard of care.[7][Level of evidence A2]
Sources: 7 · Level of evidence A2
Grade 3 or 4 cytokine release syndrome occurred in 6% of patients, and grade 3 or 4 neurotoxicity occurred in 21% of patients.
A prospective randomized trial included 184 patients with primary refractory disease or relapse within 12 months of initial R-CHOP chemotherapy. Patients received the CAR T-cell therapy lisocabtagene maraleucel (liso-cel), with 63% of patients receiving bridging therapy or second-line chemoimmunotherapy followed by autologous SCT.[9]
Sources: 9
A prospective randomized trial included 184 patients with primary refractory disease or relapse within 12 months of initial R-CHOP chemotherapy. Patients received the CAR T-cell therapy lisocabtagene maraleucel (liso-cel), with 63% of patients receiving bridging therapy or second-line chemoimmunotherapy followed by autologous SCT.[9]
With a median follow-up of 17.5 months, the median PFS was not reached for patients who received liso-cel and was 6.2 months for patients who received chemoimmunotherapy followed by autologous SCT (HR, 0.40; P < .0001).[9][Level of evidence B1]
Sources: 9 · Level of evidence B1
On the chemoimmunotherapy arm of the study, 53% of patients never received autologous SCT because of inadequate response, progression, or death.[9]
Sources: 9
Grade 3 cytokine release syndrome occurred in 1% of patients, and grade 3 neurotoxicity occurred in 4% of patients. There were no grade 4 or 5 occurrences.
A prospective randomized trial included 322 patients with primary refractory disease or relapse within 12 months of initial R-CHOP chemotherapy. Patients received the CAR T-cell therapy tisagenlecleucel, with most patients receiving bridging therapy to achieve response, or second-line chemoimmunotherapy followed by autologous SCT.[10]
Sources: 10
A prospective randomized trial included 322 patients with primary refractory disease or relapse within 12 months of initial R-CHOP chemotherapy. Patients received the CAR T-cell therapy tisagenlecleucel, with most patients receiving bridging therapy to achieve response, or second-line chemoimmunotherapy followed by autologous SCT.[10]
There was no difference in event-free survival (EFS) for patients in either arm (HR, 1.07; 95% CI, 0.82–1.40; P = .69).[10][Level of evidence B1]
Sources: 10 · Level of evidence B1
In the CAR T-cell therapy arm, 48% of patients received two or more cycles of chemoimmunotherapy as part of bridging therapy. This approach to bridging therapy may have led to an unacceptable number of cases of progressive disease.
In summary:
For patients with high-risk relapsing DLBCL with primary refractory disease or relapse within 12 months of R-CHOP-based chemotherapy, axi-cel and liso-cel are superior induction regimens, compared with chemoimmunotherapy with regimens like R-ICE, R-DHAP, and R-GDP (rituximab, gemcitabine, dexamethasone, and cisplatin).
The interval until patients receive CAR T cells must be minimized, optimally by using only steroids, eliminating bridging chemoimmunotherapy, and infusing the CAR T-cell product as quickly as possible.
The preference for CAR T-cell therapy over chemoimmunotherapy followed by autologous SCT does not apply to patients who relapse more than 12 months after R-CHOP therapy.
The American Society of Clinical Oncology (ASCO) has compiled guidelines for the management of adverse events in patients treated with CAR T-cell therapy.[11]
Sources: 11
Worse outcomes were reported when apheresis for CAR T-cell therapy occurred just after bendamustine therapy. In a retrospective multicenter review of 439 patients who were infused with CD-19–targeted CAR T cells, 80 patients had received prior bendamustine. With a median follow-up of 20.6 months after CAR T-cell infusion, the patients who had received prior bendamustine had a lower overall response rate (53% vs. 72%, P < .01), worse median PFS (3.1 vs. 6.2 months, P = .04), and worse median OS (4.6 vs. 23.5 months, P < .01).[12][Level of evidence C1]
Sources: 12 · Level of evidence C1
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
BMT consolidation is a treatment option for patients with relapsed lymphoma.[13] Preliminary studies indicate that approximately 20% to 40% of patients will have a long-term disease-free status, but the precise percentage depends on patient selection and the specific treatment used. Preparative drug regimens have varied; some investigators also use total-body irradiation. Similar success has been achieved using autologous marrow, with or without marrow purging, and allogeneic marrow.[14-18]
Evidence (BMT):
In a prospective randomized study (EORTC-PARMA), 215 patients in first or second relapse of aggressive lymphoma, younger than 60 years, and with no bone marrow or central nervous system involvement, were given two cycles of intensive combination chemotherapy. The 109 patients who responded were randomly assigned to receive four more cycles of chemotherapy and involved-field radiation therapy (IF-XRT) versus autologous BMT followed by IF-XRT. With a 5-year median follow-up, the EFS rate was significantly improved with transplant (46% vs. 12%). The OS rate was also significantly better with transplant (53% vs. 32%).[19][Level of evidence A1] Salvage BMT was unsuccessful for patients on the nontransplant arm whose disease relapsed.In general, patients who responded to initial therapy and who responded to conventional therapy for relapse before the BMT have had the best results.[20]
Sources: 19 · Level of evidence A1 · 20
In a prospective trial, patients who relapsed late (>12 months after diagnosis) had better OS than patients who relapsed earlier (the 8-year survival rate was 29% vs. 13%, P = .001).[21][Level of evidence C1]
Sources: 21 · Level of evidence C1
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Peripheral SCT has yielded results equivalent to standard autologous SCT.[22,23] Even patients who never experienced complete remission with conventional chemotherapy may have prolonged PFS (31% at 5 years) after high-dose chemotherapy and hematopoietic SCT if they retain chemosensitivity to reinduction therapy.[24][Level of evidence C2] Some patients who relapse after a previous autologous SCT can have durable remissions after myeloablative or nonmyeloablative allogeneic SCT.[25,26]; [27][Level of evidence C3] Reduced-intensity conditioning for allogeneic SCT typically involves fludarabine plus busulfan or fludarabine plus cyclophosphamide, with or without 2 Gy of total-body irradiation.[28]
Sources: 22 · 23 · 24 · Level of evidence C2 · 25 · 26 · 27 · Level of evidence C3 · 28
Evidence (peripheral SCT):
In a randomized prospective trial, 396 patients with DLBCL in first relapse or who were refractory to first-line therapy received either R-ICE or R-DHAP followed by autologous SCT.[29]
Sources: 29
In a randomized prospective trial, 396 patients with DLBCL in first relapse or who were refractory to first-line therapy received either R-ICE or R-DHAP followed by autologous SCT.[29]
There was no difference in 3-year EFS or OS.[29][Level of evidence A1]
Sources: 29 · Level of evidence A1
In a randomized prospective trial, 619 patients with relapsed or refractory aggressive lymphoma received either R-DHAP or R-GDP followed by autologous SCT.[30]
Sources: 30
In a randomized prospective trial, 619 patients with relapsed or refractory aggressive lymphoma received either R-DHAP or R-GDP followed by autologous SCT.[30]
At a median follow-up of 53 months, there was no difference in EFS or OS, but patients who received R-GDP reported less toxicity.[30][Level of evidence A3]
Sources: 30 · Level of evidence A3
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
In the event of disease relapse after autologous SCT, many patients receive consolidation with CAR T-cell therapy.
Multiple trials describe patients with refractory large B-cell lymphoma who underwent an infusion of T cells that were engineered to express a CAR to target the CD19 antigen expressed on the malignant B cells using three different constructs: axi-cel, tisagenlecleucel, and liso-cel.[31-35] Each study reported a complete response rate of 50% to 60% and a 2-year OS rate of 40% to 50%, but the long-term durability of response has yet to be determined in these highly-selected patients.[31-33][Level of evidence C3] This therapy is an option for patients with otherwise refractory or resistant disease. These results have been verified off-study in two reports that included 397 patients treated after U.S. Food and Drug Administration (FDA) approval.[36,37][Level of evidence C3] The highest risk patients who respond adequately may receive a subsequent allogeneic SCT consolidation in some cases if eligible.
Sources: 31 · 35 · 31 · 33 · Level of evidence C3 · 36 · 37 · Level of evidence C3
ASCO has compiled guidelines for the management of adverse events in patients treated with CAR T-cell therapy.[11]
Sources: 11
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Tafasitamab is a humanized anti-CD19 monoclonal antibody with a fucosylated Fc region to enhance antibody-dependent cellular cytotoxicity. Tafasitamab has been studied mostly in combination with lenalidomide.
Evidence (tafasitamab plus lenalidomide):
In a phase II study, 80 patients with SCT-ineligible relapsed or refractory DLBCL were treated with tafasitamab and lenalidomide. The study excluded patients with high-risk cytogenetics (MYC and BCL2 and/or BCL6 rearrangements) and those who had received more than four prior lines of therapy or prior CD19-directed therapy.[38]
Sources: 38
In a phase II study, 80 patients with SCT-ineligible relapsed or refractory DLBCL were treated with tafasitamab and lenalidomide. The study excluded patients with high-risk cytogenetics (MYC and BCL2 and/or BCL6 rearrangements) and those who had received more than four prior lines of therapy or prior CD19-directed therapy.[38]
The complete response rate was 43% and the objective response rate was 60%.
The FDA approved the combination of tafasitamab and lenalidomide for patients with relapsed or refractory DLBCL.[38][Level of evidence C3] It is unclear if using this CD19-directed therapy interferes with consolidation using CD19-CAR T cells.
Sources: 38 · Level of evidence C3
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Bispecific T-cell engagers (BiTEs) bind to CD20 (or CD19) and to CD3 to direct T cells to eliminate malignant B cells.[39]
Sources: 39
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Epcoritamab is a CD20-directed BiTE. It is given subcutaneously every 28 days until disease progression or unacceptable toxicity with weekly step-up dosing during cycle 1.
Evidence (epcoritamab):
A phase I/II trial (NCT03625037) included 157 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[40]
Sources: NCT03625037 · 40
A phase I/II trial (NCT03625037) included 157 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[40]
With a median follow-up of 10.7 months, the overall response rate was 63.1% (95% CI, 55.0%–70.6%), and the complete response rate was 38.9% (95% CI, 31.2%–46.9%).[40][Level of evidence C3]
Sources: 40 · Level of evidence C3
The median PFS was 4.4 months (95% CI, 3.0–7.9).
The median OS was not reached (95% CI, 11.3–not reached).
Cytokine release syndrome occurred in 49.7% of patients, and it was grade 3 or higher in 2.5% of patients. Immune effector cell–associated neurotoxicity syndrome (ICANS) occurred in 6.4% of patients, and it was grade 3 or higher in 0.6% of patients.
Results were not significantly different among 61 recipients of prior CD19-directed CAR T-cell therapy.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Glofitamab is a CD20-directed BiTE with bivalency for CD20. It is given intravenously every 21 days for a maximum of 12 cycles with weekly step-up dosing during cycle 1.
Evidence (glofitamab):
A phase I/II trial included 155 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[39]
Sources: 39
A phase I/II trial included 155 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[39]
With a median follow up of 12.6 months, the overall response rate was 52% (95% CI, 43%–60%), and the complete response rate was 39% (95% CI, 32%–48%).[39][Level of evidence C3]
Sources: 39 · Level of evidence C3
The median PFS was 4.9 months (95% CI, 3.4–8.1).
The estimated 12-month OS rate was 50% (95% CI, 41%–58%).
Cytokine release syndrome occurred in 63% of patients, and it was grade 3 or higher in 4% of patients. ICANS occurred in 8% of patients, and it was grade 3 or higher in 3% of patients.
Results were not significantly different among 52 recipients of prior CD19-directed CAR T-cell therapy.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Polatuzumab vedotin is a CD79b-directed monoclonal antibody conjugated to the cytotoxic agent vedotin (an antibody-drug conjugate).
Evidence (polatuzumab vedotin plus rituximab and bendamustine):
In a randomized, prospective trial, 80 patients with SCT-ineligible relapsed or refractory DLBCL were treated with either polatuzumab vedotin combined with bendamustine and rituximab (BR) or BR alone, with a primary end point of complete response.[41]
Sources: 41
In a randomized, prospective trial, 80 patients with SCT-ineligible relapsed or refractory DLBCL were treated with either polatuzumab vedotin combined with bendamustine and rituximab (BR) or BR alone, with a primary end point of complete response.[41]
The complete response rate by positron emission tomography−computed tomography scan was 40% for the polatuzumab vedotin-BR combination, compared with 18% for BR alone (P = .026).[41]
Sources: 41
Similarly, the median PFS was higher for patients who received the polatuzumab vedotin combination (9.5 months) than for the patients who received BR alone (3.7 months) (HR, 0.36; 95% CI, 0.21−0.63; P < .001); the OS was 12.4 months for patients who received the polatuzumab vedotin combination versus 4.7 months for the patients who received BR alone (HR, 0.42; 95% CI, 0.24−0.75; P = .002).[41][Level of evidence C1]
Sources: 41 · Level of evidence C1
The FDA approved the combination of polatuzumab vedotin and BR for patients with relapsed or refractory DLBCL.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Loncastuximab tesirine is a CD19-directed antibody conjugated to a pyrrolobenzodiazepine dimer cytotoxin (an antibody-drug conjugate).[42]
Sources: 42
Evidence (loncastuximab tesirine):
A phase I and subsequent phase II trial included 184 patients with SCT-ineligible relapsed or refractory DLBCL after two or more lines of therapy.
A phase I and subsequent phase II trial included 184 patients with SCT-ineligible relapsed or refractory DLBCL after two or more lines of therapy.
The overall response rate was 48.3% (95% CI, 39.9%–56.7%), and the complete response rate was 24%.[43,44][Level of evidence C3]
Sources: 43 · 44 · Level of evidence C3
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Evidence (rituximab plus lenalidomide):
In two phase II trials, 49 patients showed a 19% to 35% overall response rate to lenalidomide with rituximab.[45,46][Level of evidence C3]
Sources: 45 · 46 · Level of evidence C3
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Lymphoblastic lymphoma (LBL) is a very aggressive form of non-Hodgkin lymphoma, which occurs often but not exclusively in young patients. LBL is the lymphomatous manifestation of acute lymphoblastic leukemia (ALL). The treatment paradigms are based on trials for ALL because LBL and ALL are considered different manifestations of the same biological disease. LBL is commonly associated with large mediastinal masses and has a high tendency to spread to bone marrow and the central nervous system. For more information, see Acute Lymphoblastic Leukemia Treatment.
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Diffuse small noncleaved-cell/Burkitt lymphoma typically involves younger patients and represents the most common type of pediatric non-Hodgkin lymphoma.[1,2] High-grade B-cell lymphoma, not otherwise specified, includes lymphomas with Burkitt-like or blastoid morphology without double hit cytogenetics, and with germinal center B-cell phenotype.[3] Up to one-half of patients have a single MYC rearrangement. Optimal treatment is poorly defined because the diagnosis is rare. Burkitt lymphoma regimens with central nervous system (CNS) prophylaxis are usually chosen.[3]
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment options for diffuse small noncleaved-cell/Burkitt lymphoma include the following:
Aggressive multidrug regimens.
Sources: Aggressive multidrug regimens
CNS prophylaxis.
Sources: CNS prophylaxis
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment for diffuse small noncleaved-cell/Burkitt lymphoma is usually an aggressive multidrug regimen similar to those used for advanced-stage aggressive lymphomas (such as diffuse large cell).[4-6] Adverse prognostic factors include age older than 40 years, high serum lactate dehydrogenase (>3 times normal), Eastern Cooperative Oncology Group performance status of 2 or greater, and CNS involvement.[2] A retrospective review of 641 adult patients with Burkitt lymphoma from 30 U.S. cancer centers found a 3-year progression-free survival (PFS) rate of 64%. Nineteen percent of patients had CNS involvement, 14% had primary refractory disease, and the treatment-related mortality rate was 10%.[2]
Evidence (aggressive multidrug regimens):
Aggressive combination chemotherapy modeled after that used in childhood Burkitt lymphoma has been successful for adult patients. More than 60% of advanced-stage patients were free of disease at 5 years.[6-9]
Rituximab has been incorporated into these aggressive combination chemotherapy regimens. A nonrandomized, single-arm, prospective, multicenter trial of 363 patients, aged 16 years to 85 years, showed a 5-year PFS rate of 71% and a 5-year overall survival rate of 80%.[5][Level of evidence C1]
Sources: 5 · Level of evidence C1
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Patients with diffuse small noncleaved-cell/Burkitt lymphoma have a 20% to 30% lifetime risk of CNS involvement. CNS prophylaxis with methotrexate is recommended for all patients and is usually given as four to six intrathecal injections.[10] For more information, see Acute Lymphoblastic Leukemia Treatment.
Sources: 10 · Acute Lymphoblastic Leukemia Treatment
Evidence (CNS prophylaxis):
In a series of 41 patients treated with systemic and intrathecal chemotherapy, 44% of those who presented with CNS disease and 13% of those who relapsed with CNS involvement became long-term disease-free survivors.[11] CNS relapse patterns were similar whether or not patients received radiation therapy, but increased neurological deficits were noted among those who received radiation therapy.
Sources: 11
Lymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordDiffuse Large-Cell Lymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordNon-Hodgkin's Lymphoma
ClinicalTrials.gov recordLymphoma, Large B-Cell, Diffuse
ClinicalTrials.gov recordB-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2), Follicular Lymphoma (Phase 2), Transformed Follicular Lymphoma, Primary...
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordB-cell Malignancies
ClinicalTrials.gov recordRefractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL),...
ClinicalTrials.gov recordDiffuse Large B-cell Lymphoma
ClinicalTrials.gov recordDiffuse Large B-cell Lymphoma (DLBCL)
ClinicalTrials.gov recordNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma, Primary Mediastinal B-cell Lymphoma
ClinicalTrials.gov recordDiffuse Large B-Cell Lymphoma
ClinicalTrials.gov recordRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
ClinicalTrials.gov recordDiffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
ClinicalTrials.gov recordDLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL), Indolent...
ClinicalTrials.gov recordDiffuse Large B-cell Lymphoma
ClinicalTrials.gov recordEBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
ClinicalTrials.gov recordAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid...
ClinicalTrials.gov recordAIDS-related Diffuse Large Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Small Noncleaved Cell Lymphoma
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With...
ClinicalTrials.gov recordCutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma,...
ClinicalTrials.gov recordAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal...
ClinicalTrials.gov recordAnaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell...
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Aggressive Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,...
ClinicalTrials.gov recordContiguous Stage II Adult Diffuse Large Cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma,...
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With...
ClinicalTrials.gov recordAdult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of...
ClinicalTrials.gov recordMyelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell...
ClinicalTrials.gov recordAdult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma,...
ClinicalTrials.gov recordAcute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma,...
ClinicalTrials.gov recordB-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse...
ClinicalTrials.gov recordAnaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma,...
ClinicalTrials.gov recordAdult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large...
ClinicalTrials.gov recordB-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Malignant Neoplasm, Nodal Marginal Zone B-cell Lymphoma,...
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLeukemia, Lymphoma, Lymphoproliferative Disorder
ClinicalTrials.gov recordAdult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma,...
ClinicalTrials.gov recordAdult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid...
ClinicalTrials.gov recordCancer
ClinicalTrials.gov recordGraft Versus Host Disease, Leukemia, Lymphoma
ClinicalTrials.gov recordAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Cutaneous B-cell...
ClinicalTrials.gov recordFollicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Low Grade B-cell Lymphoma, Not Otherwise Specified,...
ClinicalTrials.gov recordB-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma, B-cell Small Lymphocytic Lymphoma, B-Cell Chronic...
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Previously Treated Myelodysplastic Syndrome, Recurrent...
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With...
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in...
ClinicalTrials.gov recordB-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse...
ClinicalTrials.gov recordAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, Extranodal...
ClinicalTrials.gov recordLarge B-cell Diffuse Lymphoma of Testis
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal...
ClinicalTrials.gov recordAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of...
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With...
ClinicalTrials.gov recordAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia...
ClinicalTrials.gov recordAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal...
ClinicalTrials.gov recordIron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid...
ClinicalTrials.gov recordAIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage I Grade 3 Follicular Lymphoma, Ann...
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Hematopoietic and Lymphoid...
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With...
ClinicalTrials.gov recordAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic...
ClinicalTrials.gov recordAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of...
ClinicalTrials.gov recordAcute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL)...
ClinicalTrials.gov recordAdult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma,...
ClinicalTrials.gov recordAdult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma,...
ClinicalTrials.gov recordAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal...
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Myeloid Leukemia in...
ClinicalTrials.gov recordRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell...
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordAggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia, Loss of Chromosome 17p, Myelodysplastic/Myeloproliferative...
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With...
ClinicalTrials.gov recordAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal...
ClinicalTrials.gov recordAcute Myeloid Leukemia, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma
ClinicalTrials.gov recordAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal...
ClinicalTrials.gov recordAIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell...
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid...
ClinicalTrials.gov recordChronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma
ClinicalTrials.gov recordAdult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous...
ClinicalTrials.gov recordExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse...
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid...
ClinicalTrials.gov recordMyelodysplastic Syndrome, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Primary Mediastinal B-Cell Lymphoma
ClinicalTrials.gov recordAdult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell...
ClinicalTrials.gov recordCancer, Neoplasms
ClinicalTrials.gov recordAdult Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma Recurrent, Lymphoma, Follicular, Marginal Zone B-Cell Lymphoma, Malignant Lymphoma - Lymphoplasmacytic, Waldenstrom...
ClinicalTrials.gov recordAdult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed...
ClinicalTrials.gov recordHodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
ClinicalTrials.gov recordRelapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov recordALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large...
ClinicalTrials.gov recordAcute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma,...
ClinicalTrials.gov recordAIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma,...
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, JAK2 Gene Mutation, Loss of Chromosome 17p, Mantle Cell...
ClinicalTrials.gov recordRecurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent...
ClinicalTrials.gov recordEpstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
ClinicalTrials.gov recordLymphoma, Non-Hodgkin
ClinicalTrials.gov recordRecurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2...
ClinicalTrials.gov recordAll Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL),...
ClinicalTrials.gov recordRelapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
ClinicalTrials.gov recordMultiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
ClinicalTrials.gov recordPrimary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
ClinicalTrials.gov recordAggressive B-Cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Treatment of Aggressive, Recurrent B-Cell Non-Hodgkin Lymphoma
CAR T-cell therapy for primary refractory disease or relapse within 1 year (or relapse after autologous SCT)
Treatment of Aggressive Stage I and Aggressive, Contiguous Stage II B-Cell Non-Hodgkin Lymphoma
Treatment of Aggressive, Noncontiguous Stage II/III/IV B-Cell Non-Hodgkin Lymphoma
COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more...
DailyMed labelMONJUVI, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and...
DailyMed labelPOLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously...
DailyMed labelRIABNI is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent....
DailyMed labelRITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent....
DailyMed labelRUXIENCE is a CD20-directed cytolytic antibody indicated for the treatment of: • Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). o Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. o...
DailyMed labelTRUXIMA (rituximab-abbs) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with: Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a...
DailyMed labelYESCARTA is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12...
DailyMed labelZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL...
DailyMed label